·
IDS Form PTO/SB/08: Substitute for for 1449A/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number 0/523,014

Filing Date February 1, 2005

First Named Inventor Yannoni et al.

Art Unit Not Yet Assigned 16.56

Complete if Known

(Use as many sheets as necessary)

Examiner Name

Not Yet Assigned Monshipow

Sheet 1 of 3 Attorney Docket Number 08702.0097-00000

Examiner		Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where	
Initials	nitials No.' Number-Kind Code ² (if known)		Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
16.76.	-	US-4,522,811	06-11-1985	Eppstein et al.		
\neg		US-4,554,101	11-19-1985	Норр		
		US-4,609,546	09-02-1986	Hiratani		
1		US-4,640,835	02-03-1987	Shimizu et al.		
		US-4,766,106	08-23-1988	Katre et al.		
		US-4,791,192	12-13-1988	Nakagawa et al.		
		US-5,116,944	05-26-1992	Sivam et al.		
		US-5,414,135	05-09-1995	Snow et al.		
ren.		US-5,864,020	01-26-1999	Bennett et al.		

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

1	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶	
R.H.		,WO 87/05330	09-11-1987	Bergh et al.			

	1	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
18.18.		"Mammalian Matchmaker Two-Hybrid Assay Kit User Manual", Clontech, PR17119 (2001).	
R.18.		ALTSCHUL et al., "Basic Local Alignment Search Tool," J. Mol. Biol., 215(3):403-10 (1990).	
14.19.		APLIN AND WRISTON, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids," CRC Crit. Rev. Biochem., 22:259-306 (1991).	
re.M.		BHADRA et al., "Pegnology: a review of PEG-ylated systems," Pharmazie, 57:5-29 (2002).	
H. 19.		BURKE, "Protein-Protein Interactions, Pathways and Screens, 21-24 (March 2003).	-
16.19.		EDGE et al., "Deglycosylation of Glycoproteins by Trifluoromethanesulfonic Acid," Anal. Biochem., 118(1):131-37 (1981).	
<i>دو.دد.</i>		FALB et al., "Chemical Genomics: Bridging the Gap Between the Proteome and Therapeutics," Current Opinion In Drug Discovery & Development 5(4):532-39 (2002).	
re.19.		FIELDS AND SONG, "A Novel Genetic System to Detect Protein-Protein Interactions," Nature, 340:245-246 (1989).	
re. pr.		FIELDS et al., "The Two-Hybrid System: An Assay for Protein-Protein Interactions," Trends in Genetics, 10:286-292 (1994).	
٦٤.٦٢.		FRALEY et al., "New Generation Liposomes: The Engineering of an Efficient Vehicle for Intracellular Delivery of Nucleic Acids," Trends Biochem. Sci., 6:77-80 (1981).	
re. rr.		GUIDEZ et al., "Recruitment of the Nuclear Receptor Corepressor N-CoR by the TEL Molety of the Childhood Leukemia-Associated TEL-AML1 Oncoprotein," Blood, 96 (7):2557-2561 (2000).	
۲۹.۲۲.		GUNSTER, et al., "Identification and Characterization of Interaction between the Vertebrate Polycomb- Group Protein BMI1 and Human Homologs of Polyhomeotic, Molecular and Cellular Biology, 17:2326-2335 (1997).	
۲۲.17.		HAKIMUDDIN et al., "A Chemical Method of the Deglycosylation of Proteins," Arch. Biochem. Biophys., 259:52 (1987).	

IDS Form PTO/SB/08: Substitute for to 149A/PTO

		<u> </u>	· - 4	20	
	Complete if Known	-40	4 E 201	18 /	
Application Number	0/523,014	2EL	10-500	12 21	
Filing Date	February 1, 2005 \	4		#1	
First Named Inventor	Yannoni et al.	19		æ/	
Art Unit	Not Yet Assigned	- VA	TRAPE.		
Examiner Name	Not Yet Assigned				•
Attorney Docket Number	08702.0097-00000				

STATEMENT BY APPLICANT
(Use as many sheets as necessary)

(Use as many sheets as necessary)

Examiner Name

Not Yet Assigned

Sheet

2 of 3 Attorney Docket Number 08702.0097-00000

	NON PATENT LITERATURE DOCUMENTS [HAN ET AL., "Emerging Targets for Anti-Inflammatory Therapy, Nature Cell Biology," 1:E39-40 (1999).	
re.re.		
K.19.	HARRIS et al., "Pegylation: A Novel Process for Modifying Pharmacokinetics," Clin. Pharmacokinet., 40:539-551 (2001).	
d. 19.	HEIDENREICH, et al., "MAPKAP Kinase 2 Phosphorylates Serum Response Factor <i>in Vitro</i> and <i>in Vivo</i> ," J. Biological Chemistry, 274(20):14434-14443 (1999).	
e. re.	HUANG et al. "LSP1 is the Major Substrate for Mitogen-activated Protein Kinase-activated Protein Kinase 2 in Human Neutrophils", Journal of Biological Chemistry, 272(1):17-19 (1997).	
e. re.	HUOT et al., "Oxidative Stress-Induced Actin Reorganization Mediated by the p38 Mitogen-Activated Protein Kinase/Heat Shock Protein 27 Pathway in Vascular Endothelial Cells," Cir. Res., 80(3):383-92 (1997).	
و. ٦٠.	JANKNECHT, "Cell Type-specific Inhibition of the ETS Transcription Factor ER81 by Mitogen-activated Protein Kinase-activated Protein Kinase 2," J. Blological Chemistry, 276(45):41856-14861 (2001).	
e.1º.	KOTLYAROV et al., "Distinct Cellular Functions of MK2, Molecular and Cellular Biology," 22 (13):4827-4835 (2002).	
e.1º.	KOTLYAROV et al., "MAPKAP Kinase 2 is Essential for LPS-induced TNF-α Biosynthesis," Nature Cell Biol., 1:94-97 (1999).	
e. 17.	KRÄMER, et al., "A Novel Isoform of the Smooth Muscle Cell Differentiation Marker Smoothelin", J Mol. Med., 77:294-98 (1999).	•
erc.	KYTE et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," J. Mol. Biol., 157:105-132 (1982).	
re. rc.	LEHNER et al., "Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-Difficient Mice Show Increased Susceptibility to Listeria Monocytogenes Infection", 168(9):4668-4673 (2002).	
16.16.	LIPMAN et al., "Rapid and Sensitive Protein Similarity Searches;" Science, 227(4693):1435-41 (1985).	
٠.١٤.	LUBAN, et al., "The Yeast Two-Hybrid System for Studying Protein-Protein Interactions," Curr. Opinion Biotechnology, 6:59-64 (1995).	
e.re.	LUZI et al., "Evolution of Shc Functions from Nematode to Human," Curr. Opin. Genetics and Development, 10:668-674 (2000).	
۲۰.۲۰.	MAHTANI et al., "Mitogen-Activated Protein Kinase p38 Controls the Expression and Postranslational Modification of Tristetraprolin, a Regulator of Tumor Necrosls Factor Alpha mRNA Stability," Molecular and Cellular Biology, 21:6461-6469 (2001).	
٠٤.١٢.	MANNINO et al., "Lipsome Mediated Gene Transfer," Biotechniques, 6(7):682-90 (1988).	
e. re .	MIGLIACCIO et al., "The p66 ^{shc} Adaptor Protein Controls Oxidative Stress Response and Life Span in Mammals," Nature, 402:309-313 (1999).	-
e.m.	NEININGER et al., "FRET-based Detection of Different Conformations of MK2," EMBO Reports, 2:703-708 (2001).	
e.rc.	NEUFELD et al., "Serine/Threonine Kinases 3pK and MAPK-activated Protein Kinase 2 Interact with the Basic Helix-Loop-Helix Transcription Factor E47 and Repress Its Transcriptional Activity," J. Biological Chemistry, 275 (27):20239-20242 (2000).	
4.19.	PEARSON, et al., "Improved Tools for Biological Sequence Comparison," Proc. Natl. Acad. Sci. USA, 85:2444-2448 (1988).	_
e. re.	RANE, et al., "p38 Kinase-dependent MAPKAPK-2 Activation Functions as 3-Phosphoinositide-dependent Kinase-2 Akt In Human Neutrophlls," J. Biological Chemistry, 276(5):3517-3523 (2001).	
re.19.	ROUSE et al., "A Novel Kinase Cascade Triggered by Stress and Heat Shock that Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins", Cell, 78:1027-10237 (1994)	
re. 14.	SHE et al., "ERKs and p38 Kinase Phosphorylate p53 Protein at Serine 15 in Response to UV Radiation, J. Biological Chemistry, 275,(27):20444-20449 (2000).	
و. ۲۰ .	SHE et al., "Role of MAP Kinases in UVB-Induced Phosphorylation of p53 at Serine 20," Oncogene 21(10):1580-9 (2002).	
رو. ۱۹۰	SMITH et al., "Overlapping Genes and Information Theory," J. Theor. Biol., 91(2):379-80 (1981).	
e.19.	SOJAR et al., "A Chemical Method for the Deglycosylation of Proteins," Arch. of Biochem. and Biophysics, 259 (1):52-57 (1987).	
1°. 1°.	STOKOE et al. "The Substrate Specificity and Structure of Mitogen-Activated Protein (MAP) Kinase-Activated Protein Kinase-2," Biochem. J. 296:843-849 (1993).	
19.70.	THOTAKURA et al., "Enzymatic Deglycosylatin of Glycoproteins," Meth. Enzymol., 138:350-59 (1987).	
re.4.	TRINEI et al., "A p-53-p66Shc Signalling Pathway Controls Intracellular Redox Status, Levels of Oxidation- Damaged DNA and Oxidative Stress-Inducted Apoptosis," Oncogene 21(24):3872-78 (2002).	

SEP 1 5 200 plete if Known IDS Form PTO/SB/08: Substitute for fg 0/523,014 Application Number February 1, 2005 Filing Date INFORMATION DISCLOSURE Yannoni et al. First Named Inventor STATEMENT BY APPLICANT Art Unit Not Yet Assigned Not Yet Assigned (Use as many sheets as necessary) Examiner Name 08702.0097-00000 Attomey Docket Number Sheet

		TERATURE DOCUMENTS	
re. 40.	VAN DER LOOP, et al., "Smoothelin, a Nove Biology, 134 (2):401-411 (1996).		
re.re.	VIDAL et al., "Survey and Summary, Yeast F Research 27(4):919-929 (1999).	orward and Reverse 'n'-hybrid Systems,"	Nucleic Acids
re.re.	International Search Report, 08-22-2005		
Examiner Signature	re. reonshi	Date Considered	7/31/07

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDC Farm I	DTO/CD/OR.	Substitute for	· farm	1//QA/DT	"

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	(Use as many sheets	as necessary)	•
Sheet	1	of	ŧ

Complete if Known Application Number 10/523,014 Filing Date February 1, 2005 First Named Inventor Yannoni Art Unit 1969 16 5 6 Examiner Name Monshipoun, Maryam Attorney Docket Number 08702.0097-00000

		U.S. PATENTS	AND PUBLISHE	U.S. PATENT APPLICAT	IONS
Examiner	Cite	Document Number	Issue or	Name of Patentee or	Pages, Columns, Lines, Where
Initials	No.1	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-	·		
		US-			
		US		······································	
		US-	1		
		US-			
		US-		*	
		US-			
		US-		•	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

	FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶	

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
4. re.		Upton, J., "California's non-profit community blood bank system," California Medical Association, 73: 1950-52 (1950).	
R.7°.		Plath, K., et al., "Characterization of the proline rich region of MAPKAP kinase 2: influence on catalytic properties and binding to the C-ABL SH3 domain in vitro," Biochemical and Biophysical Research Communications, 203: 1188-94 (1994).	
16. Le.		Supplementary partial European Search Report, mailed May 23, 2007	
R. M.		Honma, S., et al. "The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells," Endocrine Journal, 49: 371-77 (2002).	
R.R.		Yannonl, Y., et al., "P66sch interacts with MAPKAP kinase 2 and regulates its activity," FEBS Letters, 564: 205-11 (2004).	

	Date Considered 7/27/07
--	-------------------------